Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

Contact Us

Search

PD-1 inhibitor

Onco_background

Oncology Today—March 9, 2026

This week’s Oncology update highlights regulatory approvals, reimbursement…

Onco_background

Oncology Weekly News - September 8th 2025

🔬🧬 Oncology Updates: Tagrisso survival boost, J&J combo win and More…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital Trends
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Healthcare and Pharma Trends
Rare Disease News
Health Mobile Apps Reports
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Neuroscience Today—March 25, 2026
Immunology Today—March 25, 2026
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026

Tags

AAV exit abbvie ventures Acute lymphoblastic leukemia Almirall ANGPTL3 apixaban Biopharmaceuticals biosimilar breast health survey C2N Diagnostics Chiesi CNS therapeutics Diagonal Therapeutics Eisai Elixir Medical ENDO 2025 ESD Factor Bioscience FcRn inhibitors FKUI Flagship Pioneering GEMMA Biotherapeutics genome editing Hello Heart hepatitis C HER2-positive breast cancer hypotension IDH1-mutant glioma Ildong oral GLP-1 Infinity influenza innovative designs Ixo-vec gene therapy LAD-I licensing deals MedMobile modifiable risk factors moleculin biotech Neuromuscular disorders Pivekimab Sunirine RNAi RPDD Sonrotoclax Staphylococcus aureus vaccine Tavapadon

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Neuroscience Today—March 25, 2026
Immunology Today—March 25, 2026
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Obesity Today—March 24, 2026
Endocrinology Today—March 24, 2026

TAGS

AAV exit abbvie ventures Acute lymphoblastic leukemia Almirall ANGPTL3 apixaban Biopharmaceuticals biosimilar breast health survey C2N Diagnostics Chiesi CNS therapeutics Diagonal Therapeutics Eisai Elixir Medical ENDO 2025 ESD Factor Bioscience FcRn inhibitors FKUI Flagship Pioneering GEMMA Biotherapeutics genome editing Hello Heart hepatitis C HER2-positive breast cancer hypotension IDH1-mutant glioma Ildong oral GLP-1 Infinity influenza innovative designs Ixo-vec gene therapy LAD-I licensing deals MedMobile modifiable risk factors moleculin biotech Neuromuscular disorders Pivekimab Sunirine RNAi RPDD Sonrotoclax Staphylococcus aureus vaccine Tavapadon

Consulting Services
For Investors
Products
Case Studies
Insights
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy